A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi
- PMID:9158264
A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi
Abstract
The clinical features and response to therapy with ciprofloxacin were studied in two groups of patients: those infected by susceptible strains of Salmonella typhi and others infected by multidrug-resistant strains. There was no significant difference in the clinical presentation, laboratory findings and outcome between the two groups. Patients infected with multidrug-resistant strains, however, defervesced in significantly longer time (5.5 days) than those infected by susceptible strains (4.35 days) (p = 0.031). In areas with high prevalence of multidrug-resistant Salmonella infection, empiric treatment with quinolones or third-generation cephalosporins of all patients with suspected typhoid fever until the results of culture sensitivity tests are available may lead to better outcome.
Similar articles
- Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.Slinger R, Desjardins M, McCarthy AE, Ramotar K, Jessamine P, Guibord C, Toye B.Slinger R, et al.BMC Infect Dis. 2004 Sep 20;4:36. doi: 10.1186/1471-2334-4-36.BMC Infect Dis. 2004.PMID:15380025Free PMC article.
- Ciprofloxacin-resistant typhoid with incomplete response to cefotaxime.Prabha Adhikari MR, Baliga S.Prabha Adhikari MR, et al.J Assoc Physicians India. 2002 Mar;50:428-9.J Assoc Physicians India. 2002.PMID:11924574No abstract available.
- Clinical resistance to ciprofloxacin in Salmonella typhi.Rodrigues C, Mehta A, Andrews R, Joshi VR.Rodrigues C, et al.J Assoc Physicians India. 1998 Mar;46(3):323-4.J Assoc Physicians India. 1998.PMID:11273362No abstract available.
- Typhoid fever.Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ.Parry CM, et al.N Engl J Med. 2002 Nov 28;347(22):1770-82. doi: 10.1056/NEJMra020201.N Engl J Med. 2002.PMID:12456854Review.No abstract available.
- Quinolones in Salmonella typhi infection.DuPont HL.DuPont HL.Drugs. 1993;45 Suppl 3:119-24. doi: 10.2165/00003495-199300453-00020.Drugs. 1993.PMID:7689442Review.
Cited by
- Reference group choice and antibiotic resistance outcomes.Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y.Kaye KS, et al.Emerg Infect Dis. 2004 Jun;10(6):1125-8. doi: 10.3201/eid1006.020665.Emerg Infect Dis. 2004.PMID:15207068Free PMC article.
- Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi.Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, Misra A.Kadhiravan T, et al.BMC Infect Dis. 2005 May 18;5:37. doi: 10.1186/1471-2334-5-37.BMC Infect Dis. 2005.PMID:15904505Free PMC article.
- Current trends in typhoid Fever.Crum NF.Crum NF.Curr Gastroenterol Rep. 2003 Aug;5(4):279-86. doi: 10.1007/s11894-003-0064-0.Curr Gastroenterol Rep. 2003.PMID:12864957Review.
- Mechanism of therapeutic effectiveness of cefixime against typhoid fever.Matsumoto Y, Ikemoto A, Wakai Y, Ikeda F, Tawara S, Matsumoto K.Matsumoto Y, et al.Antimicrob Agents Chemother. 2001 Sep;45(9):2450-4. doi: 10.1128/AAC.45.9.2450-2454.2001.Antimicrob Agents Chemother. 2001.PMID:11502513Free PMC article.